Portolano Cavallo

Life Sciences

Blog

9 Apr 20
COVID-19 emergency: increasingly dematerialized prescriptions
In order to reduce the spread of Covid-19, on March 19 the Head of the Civil Protection Department adopted an ordinance (“Ocdpc 651/2020” or “Ordinance“) allowing a citizen to receive from his/her physician an electronic prescription number (numero di ricetta elettronica – “NRE“), which is necessary to get a prescription drug from a pharmacy, without going to the doctor’s office.
9 Apr 20
AIFA: latest indications for "remote" clinical trials during the COVID-19 health emergency
On April 7, 2020, the Italian Medicines Agency (“AIFA”) provided guidance on the management of clinical trials in light of the restrictive measures adopted by the Government against the COVID-19 pandemic.
8 Apr 20
COVID-19 emergency: clinical trials and early access to drugs
To address the current emergency caused by COVID-19, several initiatives have been undertaken at the regulatory level to promote and facilitate clinical trials and early access to drugs.
6 Apr 20
The Regulation (EU) 2020/354 revises and updates the list of intended uses of feed intended for particular nutritional purposes
On 4 March 2020, the Commission published the Regulation (EU) 2020/354 (“Reg. (EU) 2020/354”) establishing a list of intended uses of feed intended for particular nutritional purposes, repealing Directive 2008/38/EC (“Dir. 2008/38/EC”).
Medical Devices Regulation: European Commission adopted a proposal to postpone the date of application of the MDR by one year, until 26 May 2021
31 Mar 20
COVID-19 and consumer protection: the impact on selling and advertising practices and early reactions from relevant Italian bodies
How coronavirus impacted sales and advertising from a practical standpoint
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the Life Sciences-Healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and Venture Capital transactions.

Close
October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Search
Follow us on
Follow us on